Immune Modulation - Boosting the immune system Flashcards

1
Q

What immune response does immune memory depend on?

A

Adaptive immune response: B and T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Name the features of the adaptive immune response.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are antigen presenting cells?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What events follow exposure to antigen?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Summarise the T cell response.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How long does T cell memory last? Where does T memory lie? How do they respond to activation?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the B cell response.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How long does B cell memory last? What happens during secondary infection?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What do we want from a vaccine?

A
  • Memory (to generate protective, long-lasting immune response)
  • No adverse reactions
  • Practical (single shot, easy storage, cheap)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the aim of a vaccine for influenza?

A
  • Although CD8 T cells control the viral load, the antibody is responsible for providing a protective response
  • Haemagglutinin (HA) is the membrane fusion glycoprotein of influenza virus (i.e. a target for ABs)
  • These antibodies can be detected using a haemagglutinin inhibition assay__:
    • If normal red cells in a dish → clump at the bottom forming a red spot
    • If add influenza virus to RBCs, the HA will make cells stick together → diffuse coloration across the well
    • If add serum of someone who has a lot of ABs against HA with the virus and red cells, it will inhibit the HA from causing the above effect → cells clumping at the bottom as if the virus was not present
    • Can be done on large scale (lots of wells containing blood and virus with dilutions of patient’s serum)
      • Higher the dilution with an inhibitory effect, the greater level of antibodies the patient has against HA
      • The higher the antibody level the lower the likelihood of infection
      • Antibody protection begins 7 days after vaccine and protection can last for around 6 months
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the aim of Tuberculosis protection? How do we test for protection

A
  • BCG = attenuated strain of bovine tuberculosis
    • Provides some protection against primary infection
    • Mainly provides protection against progression to active TB
    • T cell response is important in protection
    • Mantoux Test – checks for previous exposure to TB:
      • Inject a small amount of liquid tuberculin (AKA purified protein derivative / PPD) intradermally
      • Area of injection is examined 48-72 hours after tuberculin injection
      • The reaction is an area of swelling around the injection site
      • Positive reaction wheal:
        • >5mm (high-risk – i.e. immunocompromised, living with someone with TB)
        • >10mm (medium-risk – i.e. healthcare workers)
        • >15mm (low-risk)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the different types of vaccines?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are live attenuated vaccines? What are examples of them?

A
  • Live attenuated vaccines (e.g. MMR, BCG, Yellow fever, Typhoid, Polio (Sabin), Vaccinia)
    • The organism is modified to limit pathogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the advantages of live vaccines?

A
  • Establishes infections (ideally mild symptoms)
  • Raises broad immune response to multiple antigens (offer protection against different strains)
  • Activates all phases of immune system (T cells, B cells – local IgA, humoral IgG, etc.)
  • Often confer life-long immunity after one dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the disadvantages of live vaccines?

A
  • Disadvantages:
    • Storage problems
    • Possible reversion to virulence
    • Spread to contacts (i.e. spread to immunocompromised/immunosuppressed)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Give examples of inactivated, component and toxoid vaccines.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the advantages of inactivated vaccines?

A
  • No mutation or reversion
  • Can be used in immunodeficient patients
  • Easier storage
  • Lower cost
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the disadvantages of inactivated vaccines?

A
  • Often do not follow normal route of infection
  • May have poor immunogenicity
  • May need multiple injections
  • May require conjugates or adjuvants
19
Q

What is a conjugate vaccine? Give examples.

A
20
Q

What is an adjuvant? What does it stimulate?

A

Cells from the innate immune system.

21
Q

Explain the use of mRNA vaccines in SARS-CoV

A
22
Q

How do you make mRNA vaccines?¿

A
23
Q

How do mRNA vaccines work?

A
24
Q

How do adenovirus vector vaccines work? What are examples of them?

A
25
Q

How do dentritic cell vaccines work?

A
26
Q

Describe the Sipuleucal-T Provenge.

A
  • Dendritic cell vaccines (e.g. Sipuleucel-T Provenge – an immunotherapy against prostate cancer):
    • Used against tumours where dendritic cell function may be compromised
    • Take a patient’s dendritic cells and load them with a tumour antigen and reintroduce them to the patient to try and boost the immune response against the tumour antigens
    • Requires antigens specific to the tumour and distinct from normal cells
27
Q

What are haematopoietic stem cell transplantation? How is it done? What are the indications?

A
28
Q

How do we replace antibodies?

A
29
Q

What are the indications of antibody replacement therapy?

A
30
Q

What are the types of replacement of missing components

A
  • Haematopoietic Stem cell transplantation
  • Antibody replacement therapy
    • Specific immunglobulin
  • Adaptive cell transfer - T cells
31
Q

When do you give specific immunoglobulins?

A
32
Q

What are the types of T cell transfer being used?

A
33
Q

How do you carryout virus specific T cell therapy? What is it being used for?

A
  • ViS-T Virus specific T cell therapy:
    • I.E. in EBV in those immunosuppressed to prevent development of B cell lymphoproliferative disease
    • (1) Blood is taken from the patient or from a matched individual
    • (2) Peripheral blood lymphocytes isolated → stimulated with EBV peptides
    • (3) Expansion of EBV-specific T cells → infused back into the patient
      • This is done without any stimulation of B-cells, hence no B cell lymphoproliferative disease

EBV and adenovirus

34
Q

How do you carry out Tumour infiltrating lymphocyte T cell therapy?

A
  • TIL-T Tumour infiltrating T cells (TIL – T cell therapy):
    • (1) Remove tumour from patient
    • (2) Stimulate T cells within tumour with cytokines (e.g. IL-2) so they develop a response against tumour
    • (3) Select and expand the tumour infiltrating lymphocytes and reinfuse back into the patient
35
Q

How do you carry out TCR and CAR T cell therapy?

A
  • (1) T cells taken from patient and viral / non-viral vectors used to insert gene fragments into T cells
  • (2) Gene fragments encode receptors:
    • TCR therapy → insert a gene that encodes a specific TCR (e.g. against a tumour cell antigen)
      • Recognises MHC presented peptides
        • CAR therapy → receptors are chimeric (it contains both B and T cell components)
          • Recognises cell surface CD markers
36
Q

How does Standard CAR therapy work? What does it target?

A
  • Standard CAR therapy = targeting CD19 (which is present on B cells)
    • Receptors on the CAR cell have an Ig-variable domain at the end which is joined onto the remainder of the TCR (CD28 + CD3) → signals through the usual TCR pathway but recognises CD19 through an Ig-domain → harnesses the T cells to kill the B cells
    • This is increasingly being used in ALL and NHL (not useful in solid tumours)
37
Q

What are immune checkpoint blockers?

A

CTLA 4 and PD-1

38
Q

Describe the use of ANTIBODIES specific for CTLA 4? What are the indications and complications?

A
  • Ipilimumab (antibody specific for CTL-A4) → treat melanoma:
    • CTLA4 and CD28 both expressed by T cells and both recognise the same antigens on APCs (CD80 and CD86)
      • APC CD80 and CD86 interact with CD28 → transmit a stimulatory signal
      • APC CD80 and CD86 interact with CTLA4 → transmit an inhibitory signal
    • Ipilimumab will bind to CTLA4 meaning that all of the interactions of CD80 and CD86 occur through CD28 thereby boosting the T cell response (you get more active T cells)
39
Q

Describe the use of antibodies specific for PD-1. What are the indications and complication?

A
  • Pembrolizumab and Nivolumab (specific for PD-1)  treat advanced melanoma:
    • PD-1 (prevent death 1) is found on T-regulatory cells
    • Its ligands (PDL-1 and PDL-2) are present on APCs and some tumour cells (i.e. can prevent death)
    • ABs against PD-1 prevent the inhibitory effect of binding PD1 and PD1-L → activating the T cells to kill
    • As these approaches (CTLA4 and PD-1 ABs) involve invigorating the immune response, the patients tend to develop autoimmune diseases (e.g. rheumatoid arthritis, thyroid disease, diabetes, SLE)
40
Q

When are recombinant cytokines used?

A
41
Q
A

B and T lymphocytes

42
Q
A

BCG

43
Q
A

Nivolumab, an antibody specific for PD-1